Detect subtle particle differences in biosimilars with NanoSight Pro. Strengthen comparability, reduce risk, and accelerate regulatory approval.
Biosimilars play a vital role in expanding access to biologic therapies by providing highly similar alternatives to established reference products. As patents expire, the demand for cost-effective biologics continues to grow, placing increasing pressure on developers to demonstrate equivalence with confidence and precision.
However, achieving biosimilarity is not a straightforward replication exercise. Regulatory authorities require comprehensive analytical comparability across a wide range of physicochemical and functional attributes. Developers must demonstrate that any differences between the biosimilar candidate and the originator do not impact safety, efficacy, or quality.
Among these attributes, particle-level characteristics are particularly critical. Aggregation behaviour, particle size distribution, and stability profiles directly influence immunogenicity risk and product performance. Even subtle changes in particle populations can have significant downstream consequences.
This creates a complex analytical challenge. Detecting and quantifying small but meaningful differences requires techniques that go beyond averaged measurements and provide detailed insight into heterogeneous particle systems.
With NanoSight Pro you can:
✔ Detect subtle differences in particle populations early in development
✔ Gain particle-level insight into aggregation, size, and concentration
✔ Generate reproducible, high-confidence data for regulatory submissions
NanoSight Pro sets the standard for biosimilar analysis by delivering best-in-class nanoparticle tracking analysis with true particle-level resolution. It enables developers to move beyond conventional averages and access precise, actionable insight into complex biologic formulations. In a regulatory environment where confidence is built on detail, NanoSight Pro provides the clarity and data integrity required to demonstrate equivalence with certainty.
Works with OmniTrust: Malvern Panalytical's compliance solution for the regulated environment
Biosimilar development carries hidden risks that often originate at the nanoscale, where small variations can translate into significant clinical and regulatory consequences. These risks are not always visible through conventional analytical approaches, yet they can undermine comparability and delay approval.
These risks are difficult to detect because they are often masked within complex and heterogeneous particle populations. Conventional techniques typically rely on ensemble measurements, which average out critical differences. As a result, low-abundance or overlapping particle populations may go unnoticed, limiting the ability to fully characterise biosimilar equivalence.
NanoSight Pro addresses these limitations by enabling direct, particle-by-particle analysis through nanoparticle tracking analysis. By simultaneously measuring particle size and concentration while visualising particles in real time, it reveals subtle differences that would otherwise remain hidden.
NanoSight Pro combines sensitivity, precision, and real-time visualisation to expose nanoscale risks early in development. This empowers teams to take proactive action, strengthen comparability strategies, and build more robust, defensible data packages for regulatory success.
Many biosimilar programmes encounter challenges late in development, when changes in particle behaviour begin to impact product performance. Subtle differences that were not detected early can become amplified during scale-up, storage, or real-world handling conditions.
These late-stage failures are often linked to nanoscale variations in aggregation, particle concentration, or distribution. Without the ability to resolve these differences early, developers risk costly delays, additional studies, or regulatory setbacks.
NanoSight Pro addresses this challenge through nanoparticle tracking analysis, enabling direct visualisation and measurement of individual particles in solution. By capturing particle size and concentration on a particle-by-particle basis, it provides early insight into differences that would otherwise remain hidden.
With its ability to deliver high-resolution, early-stage insight, NanoSight Pro establishes a new benchmark for risk reduction in biosimilar development. By identifying critical differences before they escalate, it enables more efficient development pathways and reduces the likelihood of late-stage failure.
Biosimilar comparability depends on the ability to detect even the smallest deviations from the reference product. NanoSight Pro provides the sensitivity required to identify low-level aggregates and subtle shifts in particle populations that may impact product quality.
By analysing particles individually rather than relying on averaged signals, NanoSight Pro reveals heterogeneity that traditional techniques may overlook. This allows for a more accurate and complete understanding of sample composition.
With NanoSight Pro, you can:
✔ Detect low-abundance aggregates with high sensitivity
✔ Resolve overlapping particle size distributions with clarity
✔ Quantify particle concentration across defined size ranges
NanoSight Pro redefines sensitivity in biosimilar analysis. As a best-in-class platform, it enables detection of critical differences at the earliest stages, supporting stronger comparability assessments and ensuring that even the most subtle variations are fully understood and controlled.
Regulatory success depends on the strength and defensibility of analytical data. NanoSight Pro enables precise, reproducible measurement of particle characteristics, supporting robust comparability assessments between biosimilars and reference products.
By delivering detailed insight into particle behaviour, NanoSight Pro helps build a comprehensive analytical package that supports regulatory expectations and reduces uncertainty.
With NanoSight Pro, you can:
✔ Generate reproducible data to support regulatory submissions
✔ Compare biosimilar and reference products with confidence
✔ Strengthen analytical evidence for demonstrating equivalence
By providing consistent, high-quality data at the particle level, NanoSight Pro sets the standard for analytical robustness. Its best-in-class performance ensures that comparability assessments are built on strong, defensible evidence, helping to streamline regulatory review and accelerate approval timelines.
Biosimilar formulations are inherently complex, often containing heterogeneous particle populations influenced by formulation conditions, processing, and storage. Understanding how these particles behave in solution is essential for ensuring stability and performance.
NanoSight Pro provides real-time visualisation of particles in their native environment, enabling deeper insight into aggregation, dispersion, and interactions within the formulation.
With NanoSight Pro, you can:
✔ Characterise heterogeneous particle populations in detail
✔ Monitor changes in particle behaviour under stress conditions
✔ Understand the impact of formulation and process variables
NanoSight Pro transforms how scientists understand complex biologic systems. By revealing particle behaviour in real time, it provides the insight needed to optimise formulations, improve stability, and ensure consistent product performance.
NanoSight Pro delivers the analytical depth required to meet the demands of modern biosimilar development. By enabling direct, particle-level analysis, it provides a clearer, more accurate picture of complex biologic formulations.
This level of insight supports stronger comparability assessments, reduces development risk, and accelerates progress toward regulatory approval.
✔ Nanoparticle tracking analysis for particle-by-particle measurement
✔ Direct visualisation of particles in solution
✔ High-resolution particle size distribution analysis
✔ Accurate particle concentration measurement
✔ Detection of low-abundance aggregates
✔ Improved reproducibility across experiments
✔ Enhanced sensitivity compared to ensemble techniques
✔ Early identification of formulation differences
✔ Stronger, more defensible analytical data
✔ Reduced risk of late-stage failure and delays
NanoSight Pro is the definitive solution for biosimilar analysis. Combining precision, sensitivity, and reproducibility, it sets the industry standard for nanoparticle characterisation in biologics. By turning nanoscale complexity into clear, actionable insight, it enables organisations to reduce risk, strengthen regulatory submissions, and accelerate the successful delivery of biosimilar therapies.
Analyse ADC heterogeneity and stability with NanoSight Pro. Detect aggregation early and optimise conjugation with particle-level insight.
Characterise extracellular vesicles in cell therapy. Gain nanoscale insight into cell health, potency, and consistency with NanoSight Pro.
Analyse extracellular vesicles with precision using NanoSight Pro. Detect heterogeneity, quantify particles, and de-risk exosome development. Gain reproducible insight into vesicle behaviour in solution.
Characterise viral vectors with precision using NanoSight Pro. Measure size, concentration, and aggregation to support gene therapy development.
Characterize lipid nanoparticles with precision using NanoSight Pro to optimise delivery, stability, and performance in biopharma development.
Detect protein aggregation early with NanoSight Pro. Gain particle-level insight to improve stability, reduce risk, and accelerate biologics development.
Characterise nanomedicine particles with precision using NanoSight Pro. Improve stability, targeting, and development outcomes.
Discover how NanoSight Pro supports Quality Control and Quality Assurance by delivering reliable, reproducible data for regulatory compliant biologics and pharmaceutical development and manufacturing.
Gain reproducible insight into particle and molecular behaviour in vaccine systems. Detect instability, optimise formulations and accelerate vaccine development with Zetasizer.